Therapeutic category
Trial status
Closed - follow up complete Participating Centres
Phase IV

Full title

Aztreonam for Inhalation Solution (AZLI) for the Treatment of Exacerbations of Cystic Fibrosis

This study aims to investigate whether it is safe and effective to use one inhaled antibiotic and one via a drip, instead of the current standard of practice of two antibiotics via a drip. Participants will receive the two different treatments the next two occasions they need to be admitted to Liverpool Heart & Chest Hospital with a chest infection. On one admission they will receive two IV antibiotics, on the other admission they will receive one IV antibiotic and inhaled aztreonam (known as Cayston®). The order they receive each treatment will be picked at random. Participants will have measurements taken including lung function tests, blood tests, CF quality of life questionnaires, and sputum samples will be sent to the University of Liverpool for advanced analysis of the effect each treatment has on bugs in the lung. It is hoped that this study may help provide more information toward a much needed expansion of therapeutic options available in CF.
Trial Reference Number
Trial type
Length of participation
2 exacerbations
Aztreonam antiobiotic
Recruitment target
Last edited date
CF sponsor
Liverpool Heart and Chest Hospital NHS Foundation Trust
CF sponsor type

Who can take part?

Top inclusion criteria
  • 18 - 65 years old Pseudomonas aeruginosa in last 6 months
  • Pseudomonas aeruginosa in last 6 months
  • FEV1 25-75%
Top exclusion criteria
  • Already prescribed regular Cayston
  • Previous organ transplant
  • Documented allergy to beta-lactam antibiotics or IV Colistin

Your donation will make a difference:

Select amount